TY - JOUR
T1 - Friends or foes? Rapid determination of dissimilar colistin and ciprofloxacin antagonism of pseudomonas aeruginosa phages
AU - Danis-Wlodarczyk, Katarzyna M.
AU - Cai, Alice
AU - Chen, Anna
AU - Gittrich, Marissa R.
AU - Sullivan, Matthew B.
AU - Wozniak, Daniel J.
AU - Abedon, Stephen T.
N1 - Funding Information:
Funding: Funding was provided by the Ohio State University President’s Postdoctoral Scholars
Funding Information:
Program and Cystic Fibrosis Foundation C3 training award (Research Development Program, Grant MCCOY19RO, to K.M.D.-W.), a Gordon and Betty Moore Foundation Investigator Award (#3790, to M.B.S.), and Public Health Service funding R01AI34895 (D.J.W.), R01AI43916 (D.J.W.), and R21AI156304 (S.T.A.).
Publisher Copyright:
© 2021 by the author. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - Phage therapy is a century-old technique employing viruses (phages) to treat bacterial infections, and in the clinic it is often used in combination with antibiotics. Antibiotics, however, interfere with critical bacterial metabolic activities that can be required by phages. Explicit testing of antibiotic antagonism of phage infection activities, though, is not a common feature of phage therapy studies. Here we use optical density-based ‘lysis-profile’ assays to assess the impact of two antibiotics, colistin and ciprofloxacin, on the bactericidal, bacteriolytic, and new-virion-production activities of three Pseudomonas aeruginosa phages. Though phages and antibiotics in combination are more potent in killing P. aeruginosa than either acting alone, colistin nevertheless substantially interferes with phage bacteriolytic and virion-production activities even at its minimum inhibitory concentration (1× MIC). Ciprofloxacin, by contrast, has little anti-phage impact at 1× or 3× MIC. We corroborate these results with more traditional measures, particularly colony-forming units, plaque-forming units, and one-step growth experiments. Our results suggest that ciprofloxacin could be useful as a concurrent phage therapy co-treatment especially when phage replication is required for treatment success. Lysis-profile assays also appear to be useful, fast, and high-through-put means of assessing antibiotic antagonism of phage infection activities.
AB - Phage therapy is a century-old technique employing viruses (phages) to treat bacterial infections, and in the clinic it is often used in combination with antibiotics. Antibiotics, however, interfere with critical bacterial metabolic activities that can be required by phages. Explicit testing of antibiotic antagonism of phage infection activities, though, is not a common feature of phage therapy studies. Here we use optical density-based ‘lysis-profile’ assays to assess the impact of two antibiotics, colistin and ciprofloxacin, on the bactericidal, bacteriolytic, and new-virion-production activities of three Pseudomonas aeruginosa phages. Though phages and antibiotics in combination are more potent in killing P. aeruginosa than either acting alone, colistin nevertheless substantially interferes with phage bacteriolytic and virion-production activities even at its minimum inhibitory concentration (1× MIC). Ciprofloxacin, by contrast, has little anti-phage impact at 1× or 3× MIC. We corroborate these results with more traditional measures, particularly colony-forming units, plaque-forming units, and one-step growth experiments. Our results suggest that ciprofloxacin could be useful as a concurrent phage therapy co-treatment especially when phage replication is required for treatment success. Lysis-profile assays also appear to be useful, fast, and high-through-put means of assessing antibiotic antagonism of phage infection activities.
KW - Antibacterial therapy
KW - Bacteriophage therapy
KW - Ciprofloxacin
KW - Colistin
KW - Phage LUZ19
KW - Phage PEV2
KW - Phage ΦKMV
UR - http://www.scopus.com/inward/record.url?scp=85119611420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119611420&partnerID=8YFLogxK
U2 - 10.3390/ph14111162
DO - 10.3390/ph14111162
M3 - Article
AN - SCOPUS:85119611420
SN - 1424-8247
VL - 14
JO - Pharmaceuticals
JF - Pharmaceuticals
IS - 11
M1 - 1162
ER -